Graduate School of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Department of Infectious Diseases, Huaian Hospital of Huaian City, Huaian, Jiangsu, 223200, China.
Postgrad Med J. 2024 Apr 22;100(1183):319-326. doi: 10.1093/postmj/qgae007.
The evaluation of patients with fatty liver as defined by metabolic dysfunction-associated fatty liver disease (MAFLD) in the real world remains poorly researched. This study aimed to analyse the clinical and histological features of patients with MAFLD and nonalcoholic fatty liver disease (NAFLD) and to characterize each metabolic subgroup of MAFLD.
A total of 2563 patients with fatty liver confirmed by ultrasonography and/or magnetic resonance tomography and/or liver biopsy-proven from three hospitals in China were included in the study. Patients were divided into different groups according to diagnostic criteria for MAFLD and NAFLD, and MAFLD into different subgroups.
There were 2337 (91.2%) patients fitting the MAFLD criteria, and 2095 (81.7%) fitting the NAFLD criteria. Compared to patients with NAFLD, those with MAFLD were more likely to be male, had more metabolic traits, higher liver enzyme levels, and noninvasive fibrosis scores. Among the patients with liver biopsy, the extent of advanced fibrosis in cases with MAFLD was significantly higher than those with NAFLD, 31.8% versus 5.2% (P < .001); there was no significant difference in advanced fibrosis between obese cases and lean individuals in MAFLD (P > .05); MAFLD complicated with diabetes had significantly higher advanced fibrosis than those without diabetes (43.3% and 17.2%, respectively; P < .001).
Patients with MAFLD have a higher degree of liver fibrosis than NAFLD patients. In addition, diabetic patients should be screened for fatty liver and liver fibrosis degree.
代谢相关脂肪性肝病(MAFLD)定义的脂肪肝患者在真实世界中的评估仍研究不足。本研究旨在分析 MAFLD 和非酒精性脂肪性肝病(NAFLD)患者的临床和组织学特征,并对 MAFLD 的每个代谢亚组进行特征描述。
共纳入中国 3 家医院的 2563 例经超声和/或磁共振断层扫描和/或肝活检证实的脂肪肝患者。根据 MAFLD 和 NAFLD 的诊断标准将患者分为不同组,并将 MAFLD 分为不同亚组。
符合 MAFLD 标准的患者有 2337 例(91.2%),符合 NAFLD 标准的患者有 2095 例(81.7%)。与 NAFLD 患者相比,MAFLD 患者更可能为男性,具有更多代谢特征,更高的肝酶水平和非侵入性纤维化评分。在接受肝活检的患者中,MAFLD 患者的晚期纤维化程度明显高于 NAFLD 患者,分别为 31.8%和 5.2%(P < .001);在 MAFLD 中,肥胖患者与非肥胖患者的晚期纤维化程度无显著差异(P > .05);MAFLD 合并糖尿病的患者与无糖尿病的患者相比,晚期纤维化程度显著更高(分别为 43.3%和 17.2%;P < .001)。
MAFLD 患者的肝纤维化程度高于 NAFLD 患者。此外,应筛查糖尿病患者的脂肪肝和肝纤维化程度。